A nomogram to predict individual prognosis in node-negative breast carcinoma

Eur J Cancer. 2012 Nov;48(16):2954-61. doi: 10.1016/j.ejca.2012.04.018. Epub 2012 May 31.

Abstract

Background: Currently, the benefit of chemotherapy (CT) in node-negative breast carcinoma (NNBC) is discussed. The evaluation of classical clinical and histological factors is limited to assess individual outcome. A statistical model was developed to improve the prognostic accuracy of NNBC.

Methods: A total of 305 node-negative breast carcinomas who underwent surgery (+/- radiotherapy) but no adjuvant treatment were selected. Putative prognosis factors including age, tumour size, oestrogen receptor (ER), progesterone receptor (PgR), Scarff-Bloom-Richardon (SBR) grading, urokinase plasminogen activator (uPA), plasminogen activator inhibitor 1 (PAI-1) and thymidine kinase (TK) were evaluated. The developed model was internally validated using Harrell's concordance index. A prognosis index (PI) was proposed and compared with Adjuvant! Online program.

Results: Age (p < 0.001), pathological tumour size (pT) (p < 0.001), PgR (p = 0.02), and PAI-1 (p ≤ 0.001) were included in the Cox regression model predicting Breast cancer specific survival (BCSS) at 5-years. Internal validation revealed a concordance index of 0.71. A PI score was derived from our nomogram. The PI score was significantly associated with BCSS (hazard ratio (HR): 4.1 for intermediate, p=0.02, HR: 8.8, p < 0.001 for high group) as compared to Adjuvant! Online score (HR: 1.4, p=0.14).

Conclusion: A nomogram can be used to predict probability survival curves for individual breast cancer patients.

Publication types

  • Comparative Study
  • Multicenter Study

MeSH terms

  • Age Factors
  • Biomarkers, Tumor / analysis
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology
  • Breast Neoplasms / surgery*
  • Carcinoma / chemistry
  • Carcinoma / mortality
  • Carcinoma / pathology
  • Carcinoma / surgery*
  • Chemotherapy, Adjuvant
  • Decision Support Techniques*
  • Disease-Free Survival
  • Female
  • France
  • Humans
  • Kaplan-Meier Estimate
  • Lymph Node Excision
  • Lymph Nodes / pathology*
  • Mastectomy, Modified Radical* / adverse effects
  • Mastectomy, Modified Radical* / mortality
  • Mastectomy, Segmental* / adverse effects
  • Mastectomy, Segmental* / mortality
  • Middle Aged
  • Multivariate Analysis
  • Nomograms*
  • Patient Selection
  • Plasminogen Activator Inhibitor 1 / analysis
  • Proportional Hazards Models
  • Radiotherapy, Adjuvant
  • Receptors, Progesterone / analysis
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Tumor Burden

Substances

  • Biomarkers, Tumor
  • Plasminogen Activator Inhibitor 1
  • Receptors, Progesterone
  • SERPINE1 protein, human